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22.1  IntroductIon
Protein acetylation is involved in the regulation of several cellular functions such as protein-protein 
interactions, protein stability, and DNA recognition by proteins. For instance, the acetylation of 
histone proteins alters gene transcription [1]. Thus, removal of acetyl groups from lysine residues 
results in compaction of chromatin and, hence, repression of gene transcription. The process of 
acetylation and deacetylation regulated by proteins with acetyltransferase activity is important for 
cellular processes. These proteins are usually known as histone acetyltransferases [2]. Nowadays, 
there is a growing interest for histone deacetylases (HDACs) because of their potential clinical 
applications [3]. HDACs have been divided into four groups. Class I and class II HDACs are similar 
to the yeast Rpd3p and Hda1p proteins. Class III HDACs are similar to the yeast transcriptional 
repressor Sir2p and are referred to as sirtuins. Class I and class II HDACs are characterized by 
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their sensitivity to inhibition by trichostatin A, while class III HDACs are dependent on nicotin-
amide adenine dinucleotide (NAD). Class IV HDACs include the deacetylase HDAC11. The focus 
of this chapter is on sirtuins (class III HDAC), which are a conserved family of NAD+-dependent 
deacetylases and named after the founding member, Saccharomyces cerevisiae silent information 
regulator 2 (Sir2) protein [4]. Its products function in a complex as transcriptional repressors or 
silencers, acting largely through histone deacetylation, at the telomeres, mating-type loci, and the 
rDNA gene loci [5] . The SIR2 gene, required for silencing of rDNA loci, is evolutionarily conserved 
from prokaryotes to humans. Sir2 is an NAD-dependent class III protein deacetylase [6,7], with 
ADP-ribosyltransferase activity in vitro. Analysis of SIRT1 enzymatic activity has revealed that 
it functions differently from previously described HDACs. Studies using purified SIRT1 revealed 
that for every acetyl lysine group removed, one molecule of NAD is cleaved, and nicotinamide 
and O-acetyl-ADP-ribose are produced (Figure 22.1). Therefore, SIRT1 appears to possess two 
enzymatic activities: the deacetylation of a target protein and the metabolism of NAD [8,9]. These 
two activities suggest that SIRT1 could act as a metabolic or oxidative sensor, regulating cellular 
machinery based on such information.
The need for NAD in the deacetylase activity of SIRT1 has led to the suggestion that enzymatic 
activity could be regulated by the concentration of NAD, the ratio NAD/NADH, or by the intracel-
lular concentration of nicotinamide [10].
Studies performed in yeast showed that Sir2 deletion leads to histone hyperacetylation. 
Subsequent studies were focused on this enzyme as a key mediator of S. cerevisiae’s replicative life 
span [10–12].
With reference to the mammalian Sir2 gene family (or sirtuins), seven homologues (SIRT1-7) 
have been characterized until now, among them the nuclear SIRT1, which is the closest homologue 
to Sir2, based on amino acid identity, and the best understood in terms of cellular activity and func-
tions. Among the nonhistone cellular substrates of SIRT1, tumor suppressor p53, the transcription 
factor nuclear factor–kappa B (NF-κB), and the FOXO family of transcription factors have been 
identified. All of them are involved in the transcriptional control of key genes in cell proliferation 
and cell survival. Moreover, SIRT1 also deacetylates the nuclear receptor peroxisome-proliferator 
activated receptor-γ (PPARγ) and its transcriptional coactivator, PPARγ coactivator-α (PGC-α), 
which regulates a wide range of metabolic activities in muscle, adipose tissues, and liver, linked 
to hepatic nuclear factor1 (HNF-4α). SIRT1 substrates, therefore, have apparent functions that can 
link nutrient availability and energy metabolism to adaptive changes in transcriptional profiles that 
affect cell survival in multiple systems.
Sirtuins are currently an object of interest in various fields of aging medicine, ranging from 
oncology to gerontology, because of their role as a longevity factor in multiple model organisms. 
The interest in SIRT1 has also intensified over the past 2 years with further discoveries of its role 
in cancer, metabolic diseases, and neurodegenerative disorders. The main focus of this review shall 
U: This reference was “hidden” 
in the manuscript:   
HYPERLINK  
“http://www.sciencedirect.com/ 
science?_ob=ArticleURL&_udi= 
B6T3K-4R0CPYN-1&_user= 
145085&_rdoc=1&_
fmt=&_orig= 
search&_sort=d&view=c&_
acct= 
C000012098&_version= 
1&_urlVersion=0&_userid= 
145085&md5=3febfdb4f8292f 
5b1c875a3309bfefc3” \l “bbib7” 
L. Gao et al., Cloning and  
functional characterization of 
HDAC11, a 
novel member of the 
humanhistonedeacetylase 
family, 
J. Biol. Chem. (2002), pp. 
25748–25755.   HYPERLINK 
“http://www.sciencedirect.com/ 
science?_ob=RedirectURL&_ 
method=outwardLink&_partner 
Name=3&_
targetURL=http%3A% 
2F%2Fdx.doi.org%2F10.1074% 
2Fjbc.M111871200&_acct= 
C000012098&_version=1&_ 
userid=145085&md5=df3290a4
6a2bbb2a312ee637c8b00206” \t 
“outwardLink”  
|   HYPERLINK “http://www. 
science direct.com/science?_
ob=Redirect 
URL&_method=outwardLink&_ 
partnerName=655&_tar-
getURL= 
http%3A%2F%2Fwww.scopus. 
com%2Fscopus%2Finward%2 
Frecord.url%3Feid%3D2-s2.0- 
0037067696%26partnerID% 
3D10%26rel%3DR3.0.0%26md
5%3D68285462a68d0a5c9de4a
17bdf54b186&_ 
acct=C000012098&_
version=1&_ 
userid=145085&md5=cac3f221 
1ee 67d052527625a0926b850” 
\t “outwardLink” |   HYPERLINK 
“http://www.sciencedirect.com/ 
science?_ob=RedirectURL&_
method=outwardLink&_
partnerName=656&_
targetURL=http%3A%2F%2F 
www.scopus.
com%2Fscopus%2 
Finward%2Fcitedby.
url%3Feid% 
3D2-s2.0-0037067696%26p
artnerID%3D10%26rel%3D
R3.0.0%26 
md 5%3D682854 
62a68d0a5c9de4a17 
bdf54b186&_acct=C000012098 
&_version=1&_
userid=145085& 
md5=5610a0b9bdc9060619ed9
2650a63ae90” \t “outwardLink” 
. Should this 
be captured?
NAD
Sirt 1
LysAc Lys
Protein Protein
FIGure 22.1 Enzymatic activity of SIRT1, using NAD+ as a cofactor, producing a deacetylated substrate 
and nicotinamide.
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be SIRT1’s role in neuronal aging and neurodegenerative diseases, and its possible modulation by a 
natural activator, resveratrol.
22.2  sIrt1 and neuroprotectIon
Several important roles of SIRT1 have been described in the central nervous system (CNS), mainly in 
neuronal development and neuroprotection. It is known that there are high levels of SIRT1 expression 
in the heart, brain, spinal cord, and dorsal root ganglia [13]. Previous studies demonstrated that high 
SIRT1 levels in the embryonic brain suggest that it might have a role in neuronal and/or brain devel-
opment. This notion is in agreement with some of the phenotypes associated with SIRT1 knockout 
mice, in which postnatal survival is infrequent and which have developmental defects [14,15].
As in other mammalian cells, SIRT1 promotes survival and stress tolerance in CNS neurons. 
However, data in this regard are scarce, because earlier studies have not used neuronal cells. In the 
adult rat brain, SIRT1 can be found in the hippocampus, cerebellum, and cerebral cortex.
Interestingly, SIRT1 expression is regulated by oxidative stress because the antioxidant vitamin 
E has been shown to reduce both the oxidative damage and the reduction of SIRT1 caused by a high 
fat and sugar diet, with the restoration of SIRT1 levels [16]. This study suggests that SIRT1 levels in 
the brain are affected by oxidative stress and energy homeostasis. A role for SIRT1 in the protec-
tion of cardiac myocytes against ischemia-induced apoptosis has been well documented [17,18]. A 
recent interesting study using organotypic hippocampal slice culture as an in vitro model of cerebral 
ischemia showed that pretreatment using resveratrol, an activator of SIRT1, mimics ischemic pre-
conditioning via SIRT1 [19]. When SIRT1 is inactivated by sirtinol after ischemic preconditioning 
or resveratrol pretreatment, neuroprotection is abolished. This study demonstrated a neuroprotec-
tive role of SIRT1 in ischemic injury, which could be elicited by a small molecule such as resvera-
trol, and it is therefore of substantial clinical interest. In contrast, another earlier report had shown 
that the sirtuin inhibitor nicotinamide enhances neuronal cell survival in acute anoxic injury [20], 
although a clear involvement of SIRT1 in this case was not clearly demonstrated.
22.3  resveratrol
Resveratrol (3,5,4′-trihydroxystilbene) was first isolated from the roots of white hellebore (Veratrum 
grandiflorum O. Loes) in 1940 and later, in 1963, from the roots of Polygonum cuspidatum, a plant 
used in traditional Chinese and Japanese medicine. Initially characterized as a phytoalexin, resvera-
trol, a polyphenol present in black grapes and its derivatives, attracted little interest until 1992, when 
it was postulated to account for some of the cardioprotective effects of red wine. Since then, dozens 
of reports have shown that resveratrol can prevent or slow down the progression of a wide variety of 
illnesses, including cancer, cardiovascular disease, and ischemic injuries, as well as enhance stress 
resistance and extend the life span of various organisms from yeast to vertebrates [21,22]. Recent 
reports indicate that resveratrol treatment alone has a range of beneficial effects in mice, but does 
not increase the longevity of ad libitum-fed animals when started midlife in contrast to high-fat 
diet–fed mice [22–24]. Chapter 24 discusses resveratrol properties in greater detail.
The mechanism by which resveratrol exerts such a range of beneficial effects across species and 
disease models is not yet clear [25], although at the beginning it was proposed that the antioxidant 
properties of this drug may explain the majority of its beneficial effects. Attempts to show its favor-
able effects in vitro have met with almost universal success, and have led to the identification of mul-
tiple direct targets for this compound. However, results from pharmacokinetic studies indicate that 
circulating resveratrol is rapidly metabolized, and cast doubt on the physiological relevance of the 
high concentrations typically used for in vitro experiments [26,27]. Further experiments are needed 
to show whether resveratrol or its metabolites accumulate sufficiently in tissues to recapitulate in 
vitro observations, or whether alternative higher-affinity targets, such as quinone reductase 2, have 
the key roles in its protective effects [28,29]. In vivo results have, therefore, become increasingly 
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important in the attempts to understand how effective resveratrol is in the treatment of different 
diseases. It is also unclear what conclusion should be drawn from the studies described so far. The 
benefits of resveratrol, as we noted above, can be explained by its antioxidant properties or better if 
this substance acts through a specific genetic pathway that has evolved to increase disease and stress 
resistance. With regard to the latter proposal, there is already an ample evidence for the existence 
of health-promoting pathways that are activated by caloric restriction. It has been known since the 
1930s that a severe lowering of caloric intake dramatically slows down the rate of aging in mam-
mals and delays the onset of numerous diseases of aging, including cancer, cardiovascular disease, 
diabetes, and neurodegeneration. The hypothesis that resveratrol might use the same pathways acti-
vated by caloric restriction in mammals is attractive because it appears to do so in lower organisms; 
however, proving this hypothesis will require a better understanding of these processes.
In reference to antioxidant action of resveratrol, it is widely accepted that resveratrol exerts anti-
oxidant effects, but it is not yet clear if this is primarily a direct scavenging effect or the result of the 
activation of pathways that up-regulate cells’ natural antioxidant defenses. Reactive oxygen species 
(ROS) have been shown to have a role in the initiation and progression of cancer by directly damag-
ing DNA and other macromolecules. In addition to its possible modulation of antioxidant enzymes 
involved in the phase II response, resveratrol has an intrinsic antioxidant capacity that could be 
related to its chemopreventive effects. In vivo, resveratrol has been shown to increase plasma antiox-
idant capacity and decrease lipid peroxidation; however, it is difficult to assess whether these effects 
are direct or the result of up-regulation of endogenous antioxidant enzymes. In addition, clinical 
trials of antioxidant molecules have yielded disappointing results, suggesting that phytochemicals 
could possess other properties that are more relevant to cancer prevention. Oxidation of low-density 
lipoprotein (LDL) particles is strongly associated with the risk of coronary heart disease and myo-
cardial infarction. Resveratrol prevents LDL oxidation in vitro by chelating copper, as well as by 
directly scavenging free radicals (although other components of red wine are superior free radical 
scavengers) [30]. Treatment of normal rats with resveratrol does not affect lipid peroxidation, as 
reflected by the presence of thiobarbituric acid-reactive substances [31]. However, resveratrol can 
be detected in LDL particles from humans after consumption of red wine, which is rich in this 
compound, and the pure compound prevents increases in lipid peroxidation induced by tumors or 
ultraviolet irradiation [32,33], in addition to blocking gentamicin-induced nephrotoxicity [34]. In 
stroke-prone, spontaneously hypertensive rats, resveratrol significantly reduces markers of oxida-
tive stress such as glycated albumin in serum, and 8-hydroxyguanosine in urine [35]. Furthermore, 
in guinea pigs, resveratrol induces the activities of QR1 and catalase in cardiac tissue, and decreases 
the concentration of ROS generated by menadione [36]. These results indicate that resveratrol can 
suppress pathological increases in the peroxidation of lipids and other macromolecules in vivo, but 
whether the mechanism is direct, indirect, or both is not yet clear.
Another mechanism by which resveratrol could combat tumor formation is induction of cell 
cycle arrest and apoptosis. The antiproliferative and proapoptotic effects of resveratrol in tumor cell 
lines have been extensively documented in vitro and are supported by down-regulation of cell cycle 
proteins and increases in apoptosis in tumor models in vivo. Although resveratrol has been found to 
target leukemic cells preferentially in vitro in some studies, the specificity of these effects remains 
unclear because other researchers have found that resveratrol inhibits growth and induces apoptosis 
in normal hematopoietic cells at similar doses. Some level of specificity could arise from the appar-
ent increased susceptibility of cycling cells to the effects of resveratrol [37]. A more precise mecha-
nism by which resveratrol could act is sensitization of tumor cells to other inducers of apoptosis. 
Resveratrol has been shown to sensitize several tumor lines, but not normal human fibroblasts, to 
TRAIL (tumor necrosis factor–related apoptosis-inducing ligand)-induced apoptosis. It remains to 
be seen whether the proapoptotic effects of resveratrol in vivo are related to these in vitro observa-
tions, or secondary to other effects, such as inhibition of angiogenesis.
The last protective mechanism related with resveratrol is its role as activator of SIRT1. Resveratrol 
increases the affinity of SIRT1 for its acetylated substrates, possibly inducing a conformational 
73516_C022.indd   332 5/11/09   10:43:43 PM
Sirtuin and Resveratrol 333
change of SIRT1 [38]. The rat brain has receptors for polyphenols such as resveratrol. This indicates 
that this substance and its derivatives can pass the blood-brain barrier, and several studies suggest 
that it may have a protective effect in some neurodegenerative processes, as we will describe below 
in greater extent. Hence, the axis SIRT1/PGC-1 activated by resveratrol (Figure 22.2) is a signaling 
pathway involved in several cellular contexts and each of the actors involved may promote a separate 
slowdown in the neurodegenerative process [39]. This neuroprotective action is very likely because 
the central factor of this signal, PGC-1, promotes mitochondrial activity, while neurodegenerative 
diseases are linked to mitochondrial failures. It is strongly suggested that the activation of the axis 
SIRT1/PGC-1 by resveratrol could be a key feature of the mechanisms of neuroprotection by this 
polyphenol and could lead to new therapeutic prospects (Figure 22.2).
22.4  resveratrol and HuntInGton’s dIsease
Using the neurotoxin 3-nitropropionic acid, a mitochondrial complex II inhibitor, and a well- 
established experimental model of Huntington’s disease, it has been reported that the beneficial 
effects of resveratrol against this neurotoxin might be attributed to its antioxidant activity [40]. 
However, several findings have converged on the notion that SIRT1’s neuroprotective effect could 
be extended to degenerating neurons. Parker and coworkers [41] showed that resveratrol, acting 
through Sir2 and SIRT1 activation, respectively, protected Caenorhabditis elegans and mouse 
neurons against the cytotoxicity of the mutant polyglutamine protein huntingtin. Huntingtin is the 
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FIGure 22.2 Scheme illustrating the effect of resveratrol on mitochondrial biogenesis and its influence 
in the antioxidant enzymes gene transcription through the SIRT1/PGC-1α/FOXO pathway. Main points of 
dysfunction for some neurodegenerative diseases are also indicated.
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product of the gene mutated in the hereditary neurodegenerative disorder Huntington’s disease, 
whose expansion of a polyglutamine stretch resulted in a mutant polypeptide that could form cyto-
toxic aggregates in neurons [42]. Although C. elegans has no huntingtin orthologue, overexpression 
of a huntingtin fragment in touch receptor neurons resulted in a gain-of-function mechanosensory 
defect that could model the disease. Both resveratrol and an increased sir-2.1 gene dosage alleviated 
the worm neuronal dysfunction in a DAF16-dependent manner. Furthermore, resveratrol decreased 
cell death associated with neurons cultured from a mutant huntingtin (109Q) knocking mice, in a 
manner that is reversible by two SIRT1 inhibitors, sirtinol and nicotinamide [43].
22.5  resveratrol and alzHeImer’s dIsease
A link between SIRT1 and Alzheimer’s disease (AD) is also becoming increasingly evident [44,45]. 
The amyloid hypothesis [46] depicts that extracellular plaques consist of aggregated beta-amyloid 
(Aβ) peptide generated from proteolytic cleavages of the amyloid precursor protein (APP) as the 
etiological agent of AD pathology [47]. Both intracellular and extracellular soluble oligomeric 
forms of Aβ could, in fact, initiate synaptic malfunctions and the onset of AD symptoms [48,49]. 
NF-κB signaling in microglia is known to be critically involved in neuronal death induced by Aβ 
peptides [50]. Chen and collaborators [51] showed that stimulation of microglia with Aβ increased 
acetylation of RelA/p65 subunit of NF-κB at lysine 310. Overexpression of SIRT1 and resveratrol 
treatment markedly reduced NF-κB signaling stimulated by Aβ and had strong neuroprotective 
effects. This result connects the known role of SIRT1 in modulating NF-κB activity [52] with AD. It 
should be kept in mind that, for AD, as with other neurodegenerative diseases, the beneficial effect 
of resveratrol is multifaceted. Its immediate effect is more likely associated with its activity as an 
antioxidant [53,54], but at a more extended time frame, its activation of SIRT1 and modulation of 
NF-κB signaling may result in other beneficial effects, such as anti-inflammation.
Another possible link between SIRT1 and AD came from the potential benefits of calorie restric-
tion (CR) on AD symptoms and progression. It is well known in the epidemiology of neurodegenera-
tive diseases that the incidence of sporadic Parkinson’s disease (PD) and AD are both correlated with 
multiple genetic factors, diet, and social behavior [55]. High calorie diets are associated with the risk 
of AD, and CR has been proposed to protect against both PD and AD[56]. Firmer evidence for this 
idea was obtained when Patel [57] showed that short-term CR substantially decreased the accumula-
tion of Aβ plaques in two AD-prone APP/presenilin transgenic mice lines, and also decreased gliosis 
marked by astrocytic activation. In another study, Wang and colleagues [58] also showed that a CR 
dietary regimen prevents Aβ peptide generation and neuritic plaque deposition in the brain of another 
mouse model of AD (Tg2576 mice). In this latter study, the authors suggested that CR resulted in 
the promotion of APP processing via the nonamyloidogenic α-secretase–mediated pathway. They 
observed a larger-than-twofold increase in the concentration of brain sAPPα (a product of α-secretase 
cleavage) and a statistically significant 30% increase in ADAM10 (a putative α-secretase) levels in 
CR animals compared to controls. There also appeared to be a moderate increase in the levels of the 
insulin degrading enzyme, which has been associated to brain amyloid clearance [59]. In another 
recent report, the same group showed that CR resulted in reduced contents of Aβ in the temporal cor-
tex of squirrel monkeys, in a manner that was inversely correlated with SIRT1 protein concentrations 
in the same brain region [60]. It is not particularly clear in the above reports whether CR’s effects in 
attenuating amyloid production were mediated through SIRT1 activation. Recent evidence suggests 
that this may indeed be the case, and may actually involve a novel signaling crosstalk [61].
22.6  resveratrol and parkInson’s dIsease
PD is a neurodegenerative disease that is also characterized at the clinical level by bradykinesia, 
tremor, and rigidity, and at the cellular level by a loss of dopamine neurons of the gray matter and 
the frequent presence of intraneuronal inclusions named Lewy bodies, mainly composed of fibrillar 
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α-synuclein [62]. Like AD, the familial form of PD concerns only a small proportion of patients 
(10%). The majority of them are suffering from a sporadic form and, if the genetic causes are fairly 
well identified, the reasons for the emergence of the sporadic contrary are still unclear. The involve-
ment of mitochondrial dysfunction in the PD has been established for more than two decades when 
it was discovered that the administration of 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine causes 
the emergence of parkinsonism in laboratory animals and also in humans, through its active metab-
olite ion MPP+, which inhibits the complex I of the chain of mitochondrial electron transport. It is 
well known that complex I is the major source of production of free radicals; the assumption is that 
the alteration of its functions could, beyond the declining production of adenosine triphosphate, 
give rise to increased oxidative stress, explaining the emergence of the disease. However, different 
authors working on different PD models conclude that SIRT1 activation does not play a major role 
in the protective effect of resveratrol against MPP+ cytotoxicity, because sirtuin inhibitors such as 
nicotinamide and sirtinol did not counteract neuroprotection by resveratrol [63]. Instead, all works 
point to propose that antioxidative actions are responsible for neuroprotection by resveratrol against 
MPP+ [63,64]. However, it has been recently described that genetic inhibition of SIRT2 via small 
interfering RNA rescued α-synuclein toxicity [65]. Furthermore, the inhibitors of this enzyme pro-
tected against dopaminergic cell death both in vitro and in a Drosophila model of PD, and found 
that inhibition of SIRT2 rescued α-synuclein toxicity and modified inclusion morphology in a cel-
lular model of PD [65]. However, increased SIRT1 expression or activity delays the toxic effects 
induced by α-synuclein, the protein that forms insoluble aggregates in several age-onset pathologies 
including PD. Resveratrol could be an interesting candidate for potential application in the treat-
ment of PD only by its antioxidant properties [63].
22.7  resveratrol In stroke and BraIn damaGe
Numerous studies have raised the possibility that resveratrol might be useful in protecting against 
brain damage following cerebral ischemia. Laboratory animals given intraperitoneal injections 
of resveratrol showed less motor impairment and significantly smaller infarct volume jointly with 
decreased delayed neuronal cell death and glial cell activation after ischemia. Similar effects 
were observed in wild-type, but not peroxisome proliferators–activated receptor-α−/−, mice [66]. 
Resveratrol administered intraperitoneally also prevented seizures induced by FeCl3, kainic acid 
[67] or pentylenetetrazole [68], and partially restored cognition in rats receiving streptozotocin 
intracerebroventricularly [69]. These results indicate that resveratrol is capable of penetrating the 
blood-brain barrier and exerts strong neuroprotective effects, even at low doses, after stroke or on 
neurotoxin-injured brain. Moreover, more studies are necessary to determine if these neuroprotec-
tive effects are mediated trough the stimulation of SIRT1 or by its antioxidant properties [21].
22.8  resveratrol and aGInG
As mentioned, in yeast, worms, and flies, extra copies of genes encoding sirtuins are associated with 
extended life span [11,70,71]. Inbred knockout mice that lack SIRT1 show developmental defects, 
have a low survival rate, and have a significantly shorter life span compared to wild-type mice, 
although out breeding seems to improve the phenotype significantly [15]. It has been postulated that 
the main function of sirtuin proteins might be to promote survival and stress resistance in times of 
adversity [72]. An evolutionary advantage arising from the ability to modify life span in response 
to environmental conditions could have allowed these enzymes to be conserved as species evolved, 
and to take on new functions in response to new stresses and demands on the organism. This could 
explain why the same family of enzymes has dramatic effects on life span in different organisms 
with seemingly dissimilar causes of aging [73]. Caloric restriction and intermittent fasting are impli-
cated in most of the theories for successful brain aging [74].The data from lower organisms have 
AU: ATP was de-
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provoked intense research into the function of sirtuin proteins in mammalian systems. An in vitro 
screen for activators of SIRT1 identified resveratrol as the most potent of 18 inducers of deacetylase 
activity [12]. Subsequent work has shown that resveratrol extends the life span of S. cerevisiae, C. 
elegans, and Drosophila melanogaster, but only if the gene that encodes Sir2 is present in these 
organisms. More recently, resveratrol was shown to extend the maximum life span of a species of 
short-lived fish by up to 59%, concomitant with the maintenance of learning and motor function 
with age and a dramatic decrease in aggregated proteins in elderly fish brains [75]; however, the 
extent to which this effect is Sir2-dependent, if at all, is not known. Moreover, resveratrol consis-
tently recapitulates the protective effects of SIRT1 overexpression in cell culture, and Sir2/SIRT1 
have been shown as essential mediators of effects on adipogenesis, NF-κB acetylation, protection 
from mutant huntingtin protein, and life span extension in lower organisms [11,41,70,76].The ques-
tion of whether enhanced SIRT1 activity and/or resveratrol treatment will increase mammalian life 
span looms large in the aging-research community.
22.9  HormesIs: axIs Between sIrt1 and resveratrol?
“Hormesis” describes the phenomenon in which a mild stress (e.g., irradiation, heat, or toxins) can 
induce a protective response against subsequent stresses [77]. This hormetic response is credited for 
the paradoxical result that mildly stressed animals outlive their unstressed counterparts, which also 
possibly applies to humans. It has been suggested that caloric restriction then activation of SIRT1 
might act as a mild stress to induce a hormetic response [78], which could account for enhanced 
stress tolerance and longevity in calorie-restricted mice, as well as the otherwise counterintuitive 
finding that such animals are better able to resist starvation [79]. In yeast, at least, this conten-
tion is strongly supported by the observation that both caloric restriction and mild stresses induce 
expression of Pnc1, an upstream activator of sirtuin proteins that is necessary and sufficient for life 
span extension [80]. The “xenohormesis hypothesis” postulates that sensing stress responses, such 
as resveratrol accumulation, in a food source might be sufficient to induce a hormetic response in 
animals eating that food. It can be imagined that throughout evolution, such stress markers in the 
surrounding vegetation would have served as strong predictors of a coming famine or direct stress 
to the animal. Reacting to these molecules would allow the hormetic response to begin ahead of 
any direct damage or energy deficit, and, more importantly, would not stake the life of the animal 
on the hope that the initial stress would be mild and/or protective. If the xenohormesis hypothesis 
is correct, then stressed plants might form an abundant reservoir for medicinal compounds that 
trigger conserved protective responses in humans [81]. The relatively low amounts of resveratrol in 
foods belie the possibility that there are numerous potential xenohormetic compounds in a stressed 
plant that could act additively or even synergistically. Indeed, another potentially xenohormetic 
compound, quercetin, behaves similarly to resveratrol in many assays and also inhibits sulfation of 
resveratrol, which predicts a greater-than-additive effect.
22.10  summary
In the past decade, sirtuin biology has traveled a long way from their original description as yeast 
NAD+-dependent class III HDACs that control yeast life span. In mammals, seven orthologues of 
Sir2 have been identified, SIRT1 to SIRT7, and the exact biological function of most of these sir-
tuins still remains only partially characterized. Of particular interest is the fact that SIRT1 not only 
deacetylates histones to mediate gene silencing, but is also able to interact with and deacetylate some 
well-known transcriptional regulators, thereby modulating specifically various biological processes. 
Hence, modulating the expression of SIRT1 or its activity, by using sirtuin activating compounds 
such as resveratrol, will have pleiotropic effects. SIRT1 activation reduces fat accumulation and adi-
pocyte differentiation through repression of the activity of the adipogenic nuclear receptor PPARγ. 
SIRT1 also promotes mitochondrial function and energy expenditure and consequently protects 
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mice from diet-induced obesity, through deacetylation and subsequent activation of PGC-1a in the 
skeletal muscle and in the brown adipose tissue. The SIRT1/PGC-1a interaction is also important in 
the liver, where SIRT1 activation upon fasting induces gluconeogenesis and prevents against hepa-
tosteatosis. In addition, SIRT1 significantly enhances insulin secretion in the pancreatic β cells. In 
combination, these studies illustrate that SIRT1 is a major modulator of metabolism. SIRT1 activa-
tion also seems to be endowed with neuroprotective activities, as suggested from the study of models 
of Huntington disease or AD (Figure 22.2). Furthermore, other sirtuins might play important roles 
in some diseases, as illustrated by SIRT2, which is down-regulated in human gliomas and could 
be involved in cancer treatment. Obviously, more studies, in animal models and humans, are still 
needed to define the exact role of sirtuins in the pathophysiology of human diseases. It can, however, 
be predicted that therapeutic interventions aiming at activating or blocking sirtuins, depending on 
the context, will one day become helpful in the treatment of human diseases.
This chapter discusses the effects of SIRT1 modulation by resveratrol that have been 
observed in vivo and possible evolutionary explanations, as they relate to the development 
of human therapeutics, based on either resveratrol itself or new, more potent compounds that 
mimic its effects.
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